Previous Article | Next Article 
Journal of Clinical Microbiology, June 2001, p. 2122-2125, Vol. 39, No. 6
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.6.2122-2125.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Simple and Efficient Method for Measuring
Anti-Toxoplasma Immunoglobulin Antibodies in Human Sera Using
Complement-Mediated Lysis of Transgenic Tachyzoites
Expressing
-Galactosidase
Caroline
Dando,1,2,
Katie E.
Gabriel,1
Jack S.
Remington,1,2,* and
Stephen F.
Parmley1,
Department of Immunology and Infectious
Diseases, Research Institute, 795 El Camino Real, Palo Alto, California
94301,1 and Division of Infectious
Diseases, Stanford University School of Medicine, Stanford, California
943052
Received 10 October 2000/Returned for modification 16 November
2000/Accepted 6 March 2001
 |
ABSTRACT |
A simple and efficient method using transgenic Toxoplasma
gondii tachyzoites expressing
-galactosidase was developed for detection of specific antibodies against the parasite in sera of
patients. The titers obtained with the new test were similar to those
obtained with the Sabin-Feldman dye test run in parallel. Although
significant changes in endpoint titers were not observed when sera
drawn sequentially at 2- to 3-week intervals were tested with both
procedures, apparent differences in antibody affinity were observed
with the new test which were not perceptible with the Sabin-Feldman dye
test. Like the Sabin-Feldman dye test, the new test is based on
complement lysis of tachyzoites, but it is much easier to perform and
the reaction is read colorimetrically instead of visually.
 |
INTRODUCTION |
Infection with Toxoplasma
gondii is routinely diagnosed by demonstration of the presence of
specific antibodies against the parasite in serum using a number of
serologic assays, including the Sabin-Feldman dye test
(9). The dye test is a complement-lysis-based assay and is
the international "gold standard" for diagnosis of toxoplasmosis
(8, 9). The dye test measures principally immunoglobulin G
(IgG) antibodies and is both sensitive and specific. Since IgG
antibodies persist in the dormant stage of the infection, detection of
these antibodies in a single sample does not provide sufficient
information regarding the timing of the initial infection or disease
manifestation. A more accurate diagnosis could be made if sera were
obtained at regular intervals. Sequential serum samples could then be
tested in parallel to determine if the IgG titers have changed over
time. A significant rise in the IgG titer is suggestive of an evolving
recently acquired infection. Conversely, a significant decrease in the
titer suggests that the infection is moving toward the chronic stage.
The dye test is considered by many diagnostic laboratories to be more
reliable than commercially available enzyme-linked immunosorbent assay
(ELISA) kits for demonstration of IgG antibodies and can often show a
change in titer between sequential samples. Unfortunately, it is time
consuming and cumbersome because it requires that live parasites
treated with each serum dilution be analyzed under the microscope.
Consequently, the dye test is presently employed by relatively few
diagnostic laboratories (8).
For the present study, we sought to improve and simplify the dye test
by using tachyzoites of T. gondii in which the gene for the
bacterial enzyme
-galactosidase (
-Gal) was introduced. This
procedure allowed the development of a microtiter assay with the
accuracy of a complement-based assay that can be read colorimetrically and avoid many of the pitfalls of the dye test.
 |
MATERIALS AND METHODS |
Construction of
-Gal plasmid.
The entire open reading
frame of the Escherichia coli
-Gal gene was amplified
from
gt11 using primers LACNSI
(5'-GGGATGCATATTACGGATTCACTGG-3') and LACPAC
(5'-GGGTTAATT AATTATTTTTGACACCAGAC-3') carrying
flanking sequences for the restriction sites NsiI and
PacI, respectively, and treated with both restriction
enzymes. The DNA fragment corresponding to the chloramphenicol
acetyltransferase open reading frame was excised from the T. gondii SAG1 promoter construct (10) with the
restriction endonucleases NsiI and PacI (Promega
Corp., Madison, Wisc.) and replaced with the
-Gal cassette. The
resulting plasmid was designated SAG1/1
-GAL.
Transfection.
Parasites were transfected using restriction
enzyme-mediated integration as described previously (1).
Briefly, 20 µg of SAG1/1
-GAL DNA was linearized with the
restriction endonuclease NotI (Promega Corp.) and phenol
extracted to eliminate residual enzymatic activity. Following ethanol
precipitation, the DNA was resuspended in cytomix buffer
(10). Immediately prior to electroporation, 100 U of
NotI was added to the cuvette containing the parasites and
DNA. Following electroporation, parasites were inoculated into T25
flasks containing human foreskin fibroblast (HFF) cells and placed
under 20 µM chloramphenicol selection. After three passages, the
parasites were cloned by limiting dilution in 96-well microtiter plates
containing HFF cells. Cloned, stable transformants expressing
-Gal
were identified in 96-well cultures grown in Dulbecco's modified
Eagle's medium lacking phenol red (Life Technologies, Rockville, Md.)
but containing 100 µM chlorophenol
red-
-D-galactopyranoside (CPRG) (Boehringer Mannheim,
Indianapolis, Ind.) as previously described (3, 7).
Parasites.
Wild-type and transgenic T. gondii (RH
strain) cells were maintained in HFF monolayers cultured in Dulbecco's
modified Eagle's medium containing 10% fetal bovine serum (Hyclone,
Logan, Utah), 25 mM HEPES, 50 U of penicillin ml
1 and 50 µg of streptomycin ml
1 incubated at 37°C in 5%
CO2. The organisms were also maintained by repeated passage
in Swiss Webster mice by intraperitoneal injection with tachyzoites.
For intraperitoneal passage of the
-Gal transgenic parasites,
organisms were suspended in phosphate-buffered saline (PBS) containing
fresh 100 µM chloramphenicol prior to injection. Peritoneal fluids
containing tachyzoites were collected at 3 days postinfection.
Serum samples.
Serum samples were provided by the Toxoplasma
Serology Laboratory of the Research Institute, Palo Alto Medical
Foundation, and by P. Thulliez from the Pasteur Institute in Paris,
France. All samples were examined in the Sabin-Feldman dye test, the
IgM-ELISA, the IgA-ELISA, and differential agglutination (AC/HS) test
(2, 5, 6, 9, 11, 12). These tests comprise the toxoplasma serologic profile (TSP) (5), and their results in
combination with the individual's clinical history were used to
classify the samples into three groups. Group 1 sera were from 8 individuals not infected with T. gondii (seronegative),
group 2 sera were from 11 individuals with a TSP suggestive of a
recently acquired infection (acute TSP) (5), and group 3 sera were from 11 individuals with a TSP suggestive of an infection
acquired in the distant past (chronic TSP) (5). An
additional group, group 4, was comprised of samples from four pregnant
women who had shown seroconversion during pregnancy. Sera from these
women were collected periodically for as long as 1 year after
seroconversion. Thirteen serum samples, eight from group 1, two from
group 2, two from group 3, and one from group 4, were used to
standardize the assay with transgenic tachyzoites and as controls.
Complement-mediated colorimetric microtiter test (
-Gal
assay).
Twenty-five microliters of serum from patients was diluted
1:4 with Hanks balanced salt solution (HBSS; Life Technologies, Rockville, Md.) and heated at 56°C for 30 min to inactivate
preexisting complement. Twofold dilutions of the serum were then made
in 96-well microtiter plates. Transgenic RH tachyzoites (
-Gal clone)
were harvested from the peritoneal cavities of mice and pelleted by centrifugation at 120 × g, washed twice with PBS
containing 1% heparin, passed four times through a 22-gauge needle to
disperse parasite aggregates, and resuspended at a concentration of
5 × 107 parasites per ml in PBS. An equal volume of
the parasite suspension was mixed with an equal volume of "accessory
factor." For the present study, accessory factor was human serum from
a single, seronegative donor that provided the source of complement for both the dye test and the current
-Gal assay. Fifty microliters of
the tachyzoite-accessory factor mixture was added to each well containing 75 µl of each serum dilution. One set of control wells contained patient serum to be diluted 1:16 without addition of the
tachyzoite-accessory factor mixture. A second set of control wells
contained only the tachyzoite-accessory factor mixture without addition
of patient serum. One hundred ten microliters of each mixture was
transferred to 0.2-ml thin-walled PCR tubes (Perkin-Elmer, Emeryville,
Calif.) and incubated at 37°C for 15 min. Thereafter, intact
parasites were pelleted by centrifugation at 1,000 × g for 5 min and 30 µl of the supernatant was transferred to a
microtiter plate.
-Gal activity was assayed in duplicate on 10 µl
of each supernatant using CPRG as the colorimetric indicator (3,
7). The absorbance at 570 nm was read on a Dynatech MR5000
microplate reader (Dynatech, Chantilly, Va.). An additional total lysis
control was included by mixing 100 µl of tachyzoite-complement
mixture with 110 µl of HBSS buffer and 40 µl of 5× reporter lysis
buffer (Promega Corp.) followed by incubation at 50°C for 10 min.
Although all specimens had been previously tested in the Sabin-Feldman dye test (9) in the Toxoplasma Serology Laboratory, serum
samples analyzed by the
-Gal assay were also tested in parallel
using the standard dye test.
 |
RESULTS |
Transgenic parasites.
Of the 20 transgenic clones positive for
-Gal expression in the 96-well cultures, 2 clones had apparently
higher levels of
-Gal expression than the other 18. During passage
and propagation in cell culture these two clones converted the CPRG
substrate in the culture medium to red much sooner than the other
clones. These two clones were expanded, and their genomic arrangements were analyzed by restriction digest and Southern blot. The Southern blot results suggested that a single copy of the
-Gal transgene had
integrated in the genome of both clones (data not shown). In addition,
the Southern blot patterns were identical, suggesting that these clones
were siblings.
Endpoint titration.
Transgenic parasites were incubated with
serum dilutions plus complement in an assay that was analogous to the
conventional dye test. However, instead of direct microscopic analysis
of the treated parasites as in the dye test, the supernatant of each reaction was assayed for the release of
-Gal from the parasites. When serum samples from patients that were previously shown to possess
IgG antibodies against T. gondii by the conventional dye test were tested in the
-Gal assay, a dilution was reached at which
the patient serum no longer stimulated a significant release of
-Gal
above the nonspecific release observed with the saline control (Fig.
1). Although it is an approximation, this
dilution is similar to the endpoint in the dye test, which is the first dilution at which less than 50% of the parasites appear unstained. Furthermore, the endpoint dilution in the
-Gal assay was within fourfold of the endpoint obtained in a parallel dye test titration (Table 1) (for example, patient 1 had a
dye test endpoint dilution of 1:256 and a
-Gal endpoint dilution of
1:256, patient 2 had a dye test endpoint dilution of 1:512 and a
-Gal endpoint dilution of 1:256, while patient 3 had a dye test
endpoint dilution of 1:4,096 and a
-Gal endpoint dilution of 1:2,048
[Fig. 1]) A similar correlation was found between the
-Gal assay
endpoint dilution and the dye test endpoint dilution in each of the
additional 20 positive sera tested (data not shown). In the
-Gal
assay, a relationship between the serum concentration and the amount of
-Gal released from the parasites was observed at numerous dilutions
preceding the endpoints. At the more concentrated serum dilutions, more
-Gal was released. Although a relationship between the serum concentration and the percentage of unstained versus stained
tachyzoites was observed in the dye test, this relationship was easily
quantified only at two or three dilutions immediately preceding the
endpoint. At the more concentrated dilutions, 100% of the tachyzoites
appeared to be unstained, making it difficult to discern differences
between adjacent dilutions.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Endpoint titrations of serum samples from three
individuals with serologic profiles consistent with chronic (patients 1 and 2) or acute (patient 3) T. gondii infection. Patients 1 and 2 were classified as having chronic TSP profiles (6)
with dye test titers of 1:256 and 1:512, respectively, negative IgM
ELISA (5) titers (1.3 and 0.9, respectively) and equivocal
patterns in the differential agglutination AC/HS (2) test
(50/100 and 50/400, respectively). Patient 3 had an acute TSP profile
(5) and a dye test titer of 1:4,096, positive IgM titer of
4.1, positive IgA ELISA (11) titer of 2.1, and an acute
AC/HS pattern (400/3,200). Absorbance readings at 570 nm are shown.
Sera from patients 1 and 2 were not tested at the 1:2,048 or 1:4,096
dilutions.
|
|
When parasites were incubated with sera from eight patients that tested
negative for
T. gondii IgG antibodies in the dye test,
no
significant release of

-Gal was detected even at a 1:4 dilution
of
the sera (data not
shown).
Sequential serum samples.
In our initial development of the
assay, we observed that sera from various patients that had similar
endpoint dilutions in the
-Gal assay released very different amounts
of
-Gal at the more concentrated dilutions (data not shown),
suggesting that the relationship between serum dilution and
-Gal
release might be exploited to discern changes in IgG titers or quality
from sequentially drawn sera which did not have obvious differences in
dye test titers. We tested sera drawn sequentially from several seroconverters whose dye test titers did not change significantly over
a 2- to 3-week period (Fig. 2). Based on
the absence of IgM antibodies and the lack of a substantial change in
the dye test titers (1:256 on 17 September 1997 and 1:64 on 7 October
1997), patient 4 was diagnosed as having an infection acquired in the more distant past. Using the
-Gal assay, similar endpoints were found (1:512) for both sera from patient 4 and no significant difference was observed in the pattern of the readings over the dilution series (Fig. 2A). However, with sera from patient 5 a very different pattern was observed (Fig. 2B), in which the later serum
sample (2 January 1997) had significantly higher readings at the more
concentrated dilutions than the sample obtained 2 weeks earlier (18 December 1996), although the endpoints for the two sera were the
same (1:2,048) in the
-Gal assay and were within twofold of each
other when run in parallel in the dye test. Although patient 5 showed
only a small increase in dye test titers over the 2-week interval
between the first and second samples (1:512 to 1:2,048), this patient
was diagnosed as having a recently acquired infection based on the
short interval between a previous dye-test-negative serum sample (19 August 1996) and the first IgG-positive serum (18 December 1996).
Similar patterns, as in Fig. 2B, were observed in this study with four
other sequentially drawn serum samples from patients with recently
acquired infection (data not shown). When sequential samples with
similar endpoints (in the dye test and
-Gal test) were compared,
significant differences in
-Gal readings were found at parallel
dilutions. This phenomenon was apparently restricted to samples
obtained during recently acquired infections, since, as observed with
patient 4 (Fig. 2A), sequential serum samples from an additional four
chronically infected patients did not display differences in
-Gal
readings at parallel dilutions, although these sera had similar
endpoints by both the dye test and the
-Gal assay (data not shown).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
Parallel endpoint titrations of sequential serum samples
obtained over 2- to 3-week periods from individuals with serologic
profiles consistent with chronic (A) or acute (B) T. gondii
infection. From patient 4 (A), two serum samples were obtained 1 year
after seroconversion, with dye test titers of 1:256 (17 September 1997)
and 1:64 (7 October 1997) and negative IgM titers (0.7 and 0.8, respectively). Patient 5 (B) seroconverted between a dye-test-negative
sample (19 August 1996) and the first dye-test-positive sample (18 December 1996). Two sequential samples from patient 5 had dye test
titers of 1:512 (18 December 1996) and 1:1,024 (2 January 1997) and
IgM-ISAGA titers of 12. Absorbance readings at 570 nm are shown.
|
|
 |
DISCUSSION |
Titers of anti- T. gondii IgG in the dye test are
defined from the endpoint dilution, which is the greatest serum
dilution where the complement-mediated lysis of tachyzoites returns to the baseline lysis that occurs from the complement accessory factor alone. In the present
-Gal assay as well, endpoint dilutions were
used to estimate T. gondii IgG titers. However, the
-Gal assay revealed differences in lysis intensity between parallel dilutions of serum specimens that had similar endpoints in both the
-Gal assay and the dye test. At the 1:64 dilutions, serum from
patient 2 had significantly higher readings than serum from patient 1 (Fig. 1), but both had endpoints of 1:256. Similarly, differences were
observed between sequential specimens from individuals that had shown
seroconversion in the recent past. For patient 5, the amount of
-Gal
released from tachyzoites during complement fixation (reflecting the
intensity of lysis) increased during a 2-week period despite the lack
of change in the endpoint titers during this period. These differences
in intensity may reflect differences in the avidity of the IgG
antibodies as they mature. The maturing antibodies from the later phase
of the infection are known to have a higher avidity (4)
and may provide a more efficient substrate for the complement system.
The rate of complement lysis is dependent on the binding affinities of
all components in the reaction, a characteristic that is similar to the
kinetic properties of enzymes, where the rate of product production is dependent on the affinity of the enzyme for the substrate. The complement cascade is initiated by the binding of the antibodies to the
parasite, and the initial rate of lysis is dependent on the affinities
of these antibodies. Although the absolute quantity of antibodies in
two serum samples may be the same, resulting in similar titration
endpoints, the higher-avidity antibodies in combination with complement
will increase the complement lesions in the tachyzoites, resulting in
an increased release of the 116-kDa
-Gal protein into the medium.
The conventional dye test makes use of the same lesions but employs a
small vital dye (methylene blue) to monitor creation of these lesions,
while in the
-Gal assay lesions are monitored as the release of a
very large macromolecule. The theory behind staining in the
conventional dye test is that complement-lysed cells are unable to
retain the dye and are not stained, while live cells retain the dye and
are stained. Small complement lesions or small numbers of lesions in
the tachyzoites may be sufficient to prevent accumulation of the dye.
Therefore, at the more concentrated serum antibody dilutions, all
tachyzoites are unstained regardless of the number or size of the
lesions. However, in the present assay it is likely that as the number of lesions per parasite or the size of the lesions increases, more of
the large
-Gal molecules are released.
In much the same way as differences in ELISA avidities are currently
being used (4), the differences in
-Gal lysis intensity might be exploited as a way to follow evolving infections and to
estimate the timing of the onset of T. gondii infection in pregnancy, where timing is critical to determination of the risks of
congenital transmission. However, the nature of these differences in
-Gal lysis would need to be explored in more detail. Furthermore, numerous sequential sera would need to be tested to establish a
correlation between lysis intensity and the timing of infection.
For the purposes of this study, the endpoint values were approximated
as the dilution point where the assay readings were similar to the
background release of
-Gal observed in a parallel saline control.
However, there were day-to-day and batch-to-batch variations in the
background release of
-Gal that were most likely due to differences
in the viability of the parasites in each batch. These differences will
have an effect on the endpoint titers, especially if the background
release is high. Indeed, we observed that the same sera would give
endpoint titers that varied by twofold when tested on different days
(data not shown). However, this twofold variance is also observed in
the dye test and is the reason sequential specimens are tested in
parallel on the same day to more accurately determine changes in
titers. Although this is a preliminary study with only a small number
of specimens tested and very few modifications were made to the method
to improve standardization, the results are promising and warrant
further exploration of this method as a routine assay. Toward that end, extensive validation and standardization will be needed. However, as an
easy method for accurately measuring IgG titers, the
-Gal assay may
be preferable to the conventional dye test.
 |
ACKNOWLEDGMENTS |
We thank Fausto Araujo, Teri Slifer, and Dorothy Gibbons for
helpful discussions and technical assistance.
This work was supported by U.S. Public Health Service grants AI04717
and AI30320.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Research
Institute, 795 El Camino Real, Palo Alto, CA 94301. Phone: (650)
853-6061. Fax: (650) 329-9853. E-mail: remington{at}pamf.org.
Present address: Lynx Therapeutics, Hayward, CA 94545.
Present address: Maxygen, Redwood City, CA 94063.
 |
REFERENCES |
| 1.
|
Black, M.,
F. Seeber,
D. Soldati,
K. Kim, and J. C. Boothroyd.
1995.
Restriction enzyme-mediated integration elevates transformation frequency and enables co-transfection of Toxoplasma gondii.
Mol. Biochem. Parasitol.
74:55-63[CrossRef][Medline].
|
| 2.
|
Dannemann, B. R.,
W. C. Vaughan,
P. Thulliez, and J. S. Remington.
1990.
Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii.
J. Clin. Microbiol.
28:1928-1933[Abstract/Free Full Text].
|
| 3.
|
Eustice, D. C.,
P. A. Feldman,
A. M. Colberg-Poley,
R. M. Buckery, and R. H. Neubauer.
1991.
A sensitive method for the detection of beta-galactosidase in transfected mammalian cells.
Biotechniques
11:739-740.
|
| 4.
|
Lappalainen, M.,
P. Koskela,
M. Koskiniemi,
P. Ammala,
V. Hiilesmaa,
K. Teramo,
K. O. Raivio,
J. S. Remington, and K. Hedman.
1993.
Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG.
J. Infect. Dis.
167:691-697[Medline].
|
| 5.
|
Liesenfeld, O.,
C. Press,
R. Flanders,
R. Ramirez, and J. S. Remington.
1996.
Study of Abbott Toxo IMx system for detection of immunoglobulin G and immunoglobulin M toxoplasma antibodies: value of confirmatory testing for diagnosis of acute toxoplasmosis.
J. Clin. Microbiol.
34:2526-2530[Abstract].
|
| 6.
|
Liesenfeld, O.,
C. Press,
J. G. Montoya,
R. Gill,
J. Isaac-Renton,
K. Hedman, and J. S. Remington.
1997.
False positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test.
J. Clin. Microbiol.
35:174-178[Abstract].
|
| 7.
|
McFadden, D. C.,
F. Seeber, and J. C. Boothroyd.
1997.
Use of Toxoplasma gondii expressing -galactosidase for colorimetric assessment of drug activity in vitro.
Antimicrob. Agents Chemother.
41:1849-1853[Abstract].
|
| 8.
|
Reiter-Owona, I.,
E. Petersen,
D. Joynson,
H. Aspock,
M. L. Darde,
R. Disko,
O. Dreazen,
H. Dumon,
R. Grillo,
U. Gross,
M. Hayde,
R. Holliman,
D. O. Ho-Yen,
K. Janitschke,
P. A. Jenum,
K. Naser,
M. Olszewski,
P. Thulliez, and H. M. Seitz.
1999.
The past and present role of the Sabin-Feldman dye test in the serodiagnosis of toxoplasmosis.
Bull. W. H. O.
77:929-935[Medline].
|
| 9.
|
Sabin, A. B., and H. A. Feldman.
1948.
Dyes as microchemical indicators of a new immunity phenomenon affecting a protozoan parasite (toxoplasma).
Science
108:660-663[Free Full Text].
|
| 10.
|
Soldati, D., and J. C. Boothroyd.
1993.
Transient transfection and expression in the obligate intracellular parasite Toxoplasma gondii.
Science
260:349-352[Abstract/Free Full Text].
|
| 11.
|
Stepick-Biek, P.,
P. Thulliez,
F. G. Araujo, and J. S. Remington.
1990.
IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis.
J. Infect. Dis.
162:270-273[Medline].
|
| 12.
|
Wong, S. Y.,
M. P. Hajdu,
R. Ramirez,
P. Thulliez,
R. McLeod, and J. S. Remington.
1993.
Role of specific immunoglobulin E in diagnosis of acute toxoplasma infection and toxoplasmosis.
J. Clin. Microbiol.
31:2952-2959[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, June 2001, p. 2122-2125, Vol. 39, No. 6
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.6.2122-2125.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.